Drug Trial Radar · NCT05838131
Study of CT071 Injection in RRMM or PPCL
Last checked: Nov 19, 2026Latest source record: Jan 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
20
Actual
Start
Apr 28, 2023
Primary completion
Jul 2025
Study completion Jul 2025
Sponsor
- Lead sponsor
- Shanghai Changzheng HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- CARsgen Therapeutics Co., Ltd.
- First posted
- May 1, 2023
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Clinical Trial to Explore the Safety and Efficacy of CT071 injection in Patients with Relapsed/Refractory Multiple Myeloma or Primary Plasma Cell Leukemia
Conditions
- Multiple Myeloma
- Primary Plasma Cell Leukemia
Interventions
Experimental: CAR-T cells InfusionDrug
Biological: chimeric antigen receptor T cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLT after CT071 infusionTime frame: Assessed from the date of first dose of study treatment until 21~28 days
- AE of Neurotoxicity and cytokine release syndrome after CT071 infusionTime frame: From first dose of study drug adminisration to end of treatment (up to 12 months)
- Adverse Events (AE) after CT071 infusionTime frame: From first dose of study drug administration to end of treatment (up to 12 months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Changzheng Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.